Nurix’s BTK Protein Degrader Shows Early Promise In Lymphoma

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.